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Abstract 
According to WHO report, more than 8 million people died globally from cancer only in year 2012 (latest year for which information is 
available) and problem was expected to increase with alarming rate in future. To target Vascular Endothelial growth factor in 
tumorous environment is an option to deprive the cancer cells from vital nutrients and hence stop the cancer progression. Vascular 
endothelial growth factors (VEGF) targeting agents administered alone or in association with other drugs are used to stop the cancer 
progression. They have been revealed for the disease improvement in the patients of advanced-stage cancers. Numbers of agents 
which can alter VEGF pathways are under investigation from different aspects regarding their efficacy in cancer treatment. In time, 
we have become gradually more aware of the fact that it is not only VEGF-Inhibited angiogenesis which blocks cancer cells growth, 
rather it involves different mechanisms. Currently five approaches are practiced to halt the VEGF signaling pathways which are; 
monoclonal ABs to target vascular endothelial growth factors and their receptors, Tyrosine kinase inhibitors of Vascular endothelial 
growth factor receptors, soluble receptors of VEGF acting as decoy receptors for VEGF, ribozymes which target VEGF mRNA and 
finally siRNA which suppress the mRNA of VEGF by RNA interference mechanism. The purpose of this article is to discuss updated 
reports on above mentioned approaches with possible drawbacks. A better and in depth understanding of these strategies which are 
used to stop VEGF pathways, will obviously revolutionize the cancer related therapeutic approaches in future. 
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INTRODUCTION 
VEGF is a signaling protein developed by cells that 
initiates the vasculogenesis and angiogenesis (Senger et 
al., 1983; Ferrara, 2016; Miller, 2016). Studies over the last 
three decades, with more than seventeen thousand papers 
published on the topic have revealed important insights into 
the process of angiogenesis by VEGF and their role in 
malignancies. There was a better understanding of 
angiogenesis process after the successful cloning of VEGF 
in 1989 (Keck et al., 1989). Only 14 year later researcher 
introduced the first VEGF-Targeting agent bevacizumab 
(moAB), in association with chemotherapy which revealed 
remedial properties toward metastatic colorectal cancer. 
After that several phase III experiments have evidenced 
and proved the beneficial effects of bevacizumab and other 
VEGF-targeted therapies, alone or in association with other 
drugs (Escudier et al., 2007; Miller et al., 2007; Motzer et 
al., 2007). In spite of extensive research on VEGF-targeted 
therapy, the detailed mechanisms of action of these 
moieties are not completely interpreted. Recently it is 
revealed that VEGF targeted approaches not merely stop 
cancer growth by ceasing angiogenesis rather there are 
different mechanisms which are responsible for the VEGF-
targeted approaches. In depth understandings of 
underlying mechanisms are mandatory for this therapy as it 
is now apparent that all VEGF-targeted therapy are not 
necessarily fruitful for the patients with different types of 
cancers.  
VEGFs and their receptors on cancer cells 
Out of five VEGF proteins (VEGFA, VEGFB, VEGFC, 
VEGFD and PGF), VEGFA (also known as VEGF) is best 
known of this family (Ferrara, 2016). Furthermore, due to 
alternative splicing, VEGFA expressed with different 
numbers of amino acids i.e. 121-, 165-, 189-, and 206- 
amino acid proteins. Specifically, VEGF165 expression is 
much higher in human solid tumors.  After the discovery of 
VEGF, research on its involvement in angiogenesis is 
much higher than any other of its function (Ferrara et al., 
2004; Ellis and Hicklin, 2008; Chung et al., 2011). 
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Recent research reveals that the VEGF is not confined 
to new blood vessels developments (Senger, 2010), rather 
it can alter the immune cells function which are in tumerous 
environment and may also affect the fibroblasts activities in 
the tumour stroma (Bahce et al., 2016). 
VEGF RTKs and Neuropilins 
Receptor tyrosine kinases are VEGFR1, VEGFR2 and 
VEGFR3 also known as FLT1, FLK1 and FLT4 
respectively (Kowanetz and Ferrara, 2006). VEGFR2 is the 
main RTK that involves in VEGF pathways in endothelial 
cells and that drives VEGF-induced angiogenesis. Some 
cancer cells express VEGFR2 which shows its involvement 
in VEGF signaling but some of the cancerous cells are 
proved to be independent from these signaling. This 
indicates the involvements of other receptor rather than 
RTKs (Kowanetz and Ferrara, 2006). 
A specific downstream signaling happens   when 
ligand binds on the vascular endothelial growth factor 
receptor tyrosine kinases (Kowanetz and Ferrara, 2006).  
VEGFR1, along with its expression on the vasculature, it 
also express on different other kinds of cells. It binds with 
tenfold higher affinity to VEGF1 but exert less effect on 
VEGF1 signaling as compared to VEGFR2. So VEGFR1 
binds to VEGF and blocks its binding to VEGFR2, in this 
way it can act as negative regulator for angiogenesis. 
VEGFR3 binds preferably with VEGFC and VEGFD on 
lymphatic endothelial cells (Laakkonen et al., 2007). 
VEGFR3 has prime role in remodeling of primary vascular 
networking in embryo development and also effects on 
post-natal lymph angiogenesis (Kukk et al., 1996;  Alitalo 
and Carmeliet, 2002). 
The NP1 and NP2 (neuropilins) serve as co-receptors 
for the VEGF, enhancing the adhering affinity of VEGF to 
VEGFR TKI receptors (Klagsbrun et al., 2002; Soker et al., 
2002; Bielenberg and Klagsbrun, 2007; Batchelor, et al., 
2007). Interestingly, current research suggests that dual 
targeting of VEGF and NP1 with antibodies is more fruitful 
than using single target (Batchelor et al., 2007). Regarding 
tumor angiogenesis, VEGF increase blood flow rate in 
tumor  by enhancing endothelial cell proliferations through 
various mechanisms i.e. increased endothelial cell 
proliferation and survival, enhanced lattice network for 
endothelial cells (Gimbrone et al., 1973; Rafii et al., 2002). 
Apart from angiogenesis related activities, VEGF has 
involvements in some other vital functions like autocrine 
signaling of tumor cells and suppression of immune system 
activities (Kaplan et al., 2005). Important thing is that 
increased blood vessels by VEGF cannot be correlated 
with increased smooth blood flow in the vessel. For 
example dilation of blood vessel can result in turbulent and 
improper blood flow. VGF induced enhanced vessels 
permeability may result in enhanced fluid pressure and 
narrowing of blood vessels (Sun et al., 2007; Yang et al., 
2007). 
 
 
Experimental VEGF-targeted strategies for solid tumor 
inhibitions 
Understanding of the fact that VEGF mediated 
signaling is important in angiogenesis has resulted in 
invention of many approaches which can target and block 
VEGF. These include antibodies which neutralize Vascular 
Endothelial Growth Factors or their receptors, Receptor 
hybrids which block VEGFs and TKIs which also bind 
selectively VEGFs. Other approaches include Ribozymes 
and siRNA which specifically bind and block RNAs for 
VEGFs (Casanovas et al., 2005). Currently, used drugs 
include bevacizumab which block VEGFs, sorafenib 
neutralizes VEGFR TKIs, and sunitimib, also blocks the 
VEGFRs. Bevacizumab was approved by FDA for clinical 
use for human MCC (metastatic colorectal cancer) and 
breast cancers alone or as a combined therapy with other 
drugs (Miller et al., 2005; Sandler et al., 2006; Kane et al., 
2006;  Batchelor et al., 2007; Goodman et al., 2007; 
Hurwitz et al., 2007). 
Monoclonal antibodies targeting VEGFs 
Monoclonal antibodies continue to be a good option for 
targeting angiogenic agents in cancer treatment (Hinoda et 
al., 2004). A famous humanized mouse monoclonal 
antibody Bevacizumab is important in different cancers 
treatment. It is in the list of the WHO’s Essential Medicines 
(Wang and Zhang 2014). It is used to target human 
Vascular Endothelial Growth Factor (Zondor and Medina, 
2004; Presta et al., 1997). It has 17 days half-life in human 
and is administrated inter venous in 1.5 hours after every 
seventeen days. It was allowed for treatment by FDA for 
different metastatic cancers in 2004 as alone or in 
combination with standard chemotherapy . It has since 
been approved for use in certain lung cancers, renal 
tumors, ovarian cancers, and brain’s 
glioblastoma (Bergsland, 2004). Earlier Bevasizumab had 
been approved for different cancers by FDA, but that 
approval was withdrawn for the breast cancer in 2014, 
when studies showed less evidence of effectiveness in 
breast cancer treatment (Kodjikian et al., 2014). Regarding 
adverse effects of bevacizumab-related therapeutics, in a 
controlled study, hypertension is a major documented side 
effect. Twenty two percent of patients who were on 
bevacizumab in combination with IFL compared to Eight 
percent of those patients taking placebo along with IFL 
were reported to have problem of hypertension. But all of 
these cases of hypertension were treated by giving oral anti 
depressive medications to patients without interruption or 
discontinuity of bevacizumab therapy. There were minor 
cases of gastrointestinal perforation on IFL plus 
bevacizumab therapy (6 out of 393 patients; 1.5 %). 
 In a phase III controlled randomized study, it was 
observed that in patients who were given combination of 
bevacizumab and interferon-alfa as first line treatment, 
there was significant increase in progression-free survival 
while in patients who were given interferon alone, there 
was no such increase reported (Escudier et al., 2007). 
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HuMV833 is a murine monoclonal anti-VEGF antibody. 
It is a humanized form of MV833 that revealed activity 
against multiple types of tumors. The melanoma and 
rhabdomyosarcoma xenografts growth were inhibited by 
the administration of this neutralizing antibody (Kim et al., 
1993). However, in phase I clinical trial (Jayso et al., 2002), 
HuMV833 showed variations in tissue distribution among 
patients, in normal organs as well as in malignant lesions. 
Because of this reason, it was not further investigated in 
upcoming trials for monoclonal antibodies action against 
cancers. 
VEGF receptor Kinases inhibitors 
Small molecule inhibitors (SMIs) are considered as one 
of the most effective drugs for targeted therapy of cancer. 
In clinical oncology, the increasing number of approved 
tyrosine kinase inhibitors (TKIs) indicates the improvement 
in attention and application of these cancer remedial tools. 
Many of these Kinase inhibitors, recently approved VEGFR 
Kinases inhibitors are in pre-clinical and clinical trials along 
with several side effects. Only small number of these 
agents has been approved for cancer therapeutics. 
Selective RTK–TKIs have revealed less harmful effects in 
contrast to multi-targeted inhibitors (Hojjat-Farsangi, 2014). 
Semaxanib (SU5416) is a tyrosine-kinase inhibitor drug 
formulated by SUGEN (a cancer therapeutic drug 
discovery company) which is the potent and selective 
inhibitor of VEGFR-2 (O'Donnell et al., 2005) and was the 
first drug regarding this category to reach clinical trials. This 
inhibitor also reveals activity in response to other VEGF 
receptor kinases, PDGFR and c-kit by imitating ATP and 
halting binding of ATP and in pre-clinical trials, it was 
seemed to stop growth and vascularization of tumor 
(Canadas et al., 2010). However, it was reported later that 
drug has more side effects with less efficacy, which led to 
the discontinuation of this drug development (Hoff et al., 
2006). On February 2002, Pharmacia, the then-parent of 
Sugen, ultimately ended Phase III clinical trials of SU5416 
in the treatment of advanced colorectal cancer due to 
discouraging results (Hoff et al., 2006). However, it was 
approved by FDA as sunitinib for treatment of renal 
carcinoma in January 2006. 
SU6668, an orally bioavailable TKI shown good pre-
clinical performance but failed to prove clinical efficacy 
against solid tumors and hence no further improvement 
occurred regarding this drug (Eichhorn et al., 2004). 
SU11248 is a fresher oral TKI that has activity against 
VEGFR-1 and 2, Sixty three patients suffering from 
metastatic kidney cancer, who failed to respond to 
interferon therapy, when given this drug in clinical trials of 
phase II showed promising effects (Ciardiello et al., 2003; 
Tuma, 2004).  
Vatalanib is another strong, powerful & selective 
VEGFR-KI among 1
st
 generation drugs, administered 
orally. It causes inhibitory effects on VEGFR-1 & 2 when 
given in µM concentrations but if given in higher 
concentrations it can also block tyrosine kinase like 
receptors of growth factors derived by platelets (Bold et al., 
2000). 
Soluble VEGF Receptor 
A decoy soluble receptor, VEGF-Trap was made by 
fusing interstitial domains of VEGFR-1 and VEGFR-2, 
which has strong affinity to fragment constant part of IgG1 
(Konner and Dupont, 2004).  
In pre-clinical studies, it revealed anti-tumor activity 
against several xenograft models i.e.  in pancreatic cancer, 
preventing advancement of the primary cancer and 
decreasing size of tumor (Byrne et al., 2003; Frischer et al., 
2004; Fukasawa and Korc, 2004). The VEGF-Trap 
produces its angiogenic effects by suppressing tumor 
vasculature, reshaping or regularizing the surviving vessels 
and by blocking the new vessels growth for tumor (Teng et 
al., 2010). 
Ribozymes 
mRNA molecules are cleaved in a sequence-specific 
manner by Ribozymes, a  RNA enzyme (Ciafre et al., 
2004). Various cancerous growth and proliferation was 
arrested by reaction of ribozymes on VEGF mRNA. Also 
ribozymes showed in vitro activity towards VEGF receptors 
(Weng and Usman, 2001). To target pre or immature 
mRNA, a stable ribozyme is used which cut downs the 
expression of both soluble and cell surface VEGFR-1. 
Normal volunteers well-sustained Angiozyme TM (also 
called RPI. 4610) (Weng and Usman, 2001). In clinical 
trials of phase II initial data with this drug showed some 
promising results but later some sever adverse side effects 
such as on site of injection, fatigue, anorexia, fever, 
constipation, vomiting, headache, abdominal pain, 
dyspnoea and nausea were reported. Although Angiozyme 
showed good safety profiles but it was ruled out from 
further development and advancement because of its lack 
in clinical effectiveness (Morrow et al., 2012). 
RNA Interference (RNAi) induced VEGF silencing 
To shape expression of gene RNAi is specific, capable 
and effective mechanism. Using RNAi for gene silencing to 
cure certain diseases assures the development of new 
class of therapeutics. Former investigations have revealed 
that RNAi of VEGF-C effectively targets breast cancer cells 
and block their metastasis in lymphatic system and also 
RNAi of VEGF inhibits angiogenesis and blocks 
retinoblastoma & Ewing’s sarcoma or bone cancer (Guan 
et al., 2005; Sun et al., 2008).  
For examination of activity and safeness of lipid 
nanoparticle siRNA formulation in humans, ALN-VSP trials 
were started, siRNAs LNP formulation targeted kinesin 
spindle protein (KSP) and VEGF, in cancer patients. 
Pharmaco dynamics suggested anti-tumor action along 
with complete suppression of metastasis from liver to 
uterus or endometrial cancer. It was also revealed that IV 
injection of ALN-VSP twice a week was secure and well 
sustained. These investigations provided certification of 
concept that RNA interference based treatments are fruitful 
in cancer research (Tabernero et al., 2013).  
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In another study RNA interference induced by siRNA 
was used to check that if the impairment in synthesis of 
VEGF can halt the development of TSP1 resistance .It was 
revealed that the growth of unaltered Fibro sarcoma tumor 
cells was reduced by systemic In-vivo administration of 
crude Anti-VEGF siRNA. Anti-VEGF siRNA not only 
retarded the growth of TSP1 resistant cancers but also 
halted their growth rate (Filleur et al., 2003). 
Still technical troubles such as stability, off target 
effects, immuno stimulation and delivery problems restrict 
the RNAi development. By optimizing the molecular 
structure and chemistry, investigators have tried to surpass 
these hurdles and improve the bioavailability and safety of 
RNA based therapeutics. 
Challenges with Anti-VEGF therapies 
First Anti-angiogenic drug has been approved by FDA 
since nine years i.e. monoclonal antibodies (bevacizumab) 
are synthesized to treat metastatic colorectal cancer. Many 
other anti-angiogenic drugs are under some stages of 
clinical investigations. Major drawbacks have been 
identified, related to utilization of this class of agents such 
as adapted resistance, by ongoing clinical and preclinical 
trials. Lack of validated predictive biomarker to analyze 
tumor progressions and therapeutic response are the major 
hurdles .For the above challenges, some molecular and 
cellular mechanisms have been provided by investigations 
in clinical and preclinical models (Shojaei, 2012). 
For patients in which VEGF therapy was effective, it 
was a misfortune that the duration of activity of therapy was 
relatively short i.e. single-agent therapy within three to eight 
etargeted drug resistance mechanisms (Bergers and 
Hanahan, 2008). The need is to formulate better agents 
and to design a combined therapy to collaborate with 
VEGF. Pre symptomatic investigations also reveals that if 
the regimens targeting the VEGF ligand develops 
resistance against a specific drug then it might b effective to 
aim other VEGF family members (Batchelor et al., 2007). 
Additionally, preclinical research has proved that therapies 
that target VEGF ligand and neuropilin can increase 
capacity of preclinical experiments (Batchelor et al., 2007). 
Currently, about 20 different types of VEGF targeted 
agents are there in clinical trials. Monoclonal antibodies 
apply a selective targeting to VEGF components and this 
method has perhaps small adverse effects due to its high 
specificity. However TKIs with off target effects can be 
advantageous because of their ability to target different 
TKIs at same time which are involved in cancer 
progression and formation of blood vessels, but relatively at 
higher costs of toxicities. Blockage of VEGF remains an 
optimistic accession in the neoplasmic treatments. 
Combined treatment against VEGF along with 
chemotherapy and radiotherapy give better results in anti-
tumor effects as compared to treating alone (Ziche et al., 
2004). RNAi therapeutics is another promising area for 
VEGF related cancer treatment but again we have to 
optimize the siRNA delivery protocols .The need is to 
design clinical models to explore the detailed pathways and 
mechanisms involved in VEGF targeting. Effects of 
targeting VEGF on cancer microenvironment as well as 
normal host tissues can be fully understood by 
interpretations of results taken from clinical investigations. 
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